A lymphocyte surface receptor that binds caml, nucleic acids encoding the same and methods of use thereof
CA 2284078 C · Owner: St. Jude Children'S Research Hospital · Inventors: Von Bulow, Gotz; Bram, Richard J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel lymphocyte receptor protein, its DNA sequence and its role in the , calcium activation pathway is described. The protein or genetically , engineered constructs encoding it are shown to increase lymphocyte response and to identify ligands of the protein receptor. Antibodies to the proteins of the invention are generated for diagnositc therapeutics. The protein and DNA can also be used for diagnostic purposes and for identifying agents for modulating the calcium induced activation pathway. A particular advantage of the present invention is that it provides lymphocyte activation of receptor found on all B cells, but only on a subset of T cells. The receptor can thus be targeted …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 3, 1998 and granted September 9, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 3, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 3, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.